QuVA Pharma

Executive Summary

QuVA Pharma is a US-based company uniquely combining sterile injectable compounding with an AI-powered analytics platform. Founded in 2021, it serves over 3,000 hospitals nationwide by providing high-quality, ready-to-administer generic drugs through its 503B outsourcing facility, while also offering the Quva BrightStream SaaS platform that leverages data to optimize hospital medication management and reduce waste. This dual model positions QuVA to address the critical shortage of sterile injectables and improve operational efficiency in healthcare. With its focus on quality and data-driven insights, the company is well-poised for growth as hospitals increasingly seek reliable compounding partners and digital solutions. As a private entity, QuVA's valuation and funding are undisclosed, but its broad hospital network and innovative approach suggest strong market traction.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of new generic sterile injectable product70% success
• Q3 2026Major hospital system contract win or expansion80% success
• Q3 2026Launch of updated BrightStream platform with enhanced AI capabilities60% success